Start trading now on Poste Italiane

BioNTech takes a long fall on Pfizer outlook: 5 big analyst cuts




— Here is your Pro Recap of the biggest analyst cuts you may have missed today: downgrades at Cummins,, BioNTech, Crown Castle, and KB Home.

subscribers got this news first.

BioNTech slashed at HSBC on lower COVID product sales forecast

HSBC downgraded BioNTech (NASDAQ:) to Hold from Buy after Pfizer ‘s (NYSE:) lowered sales projections for its COVID vaccine and treatment were worse than some analysts had anticipated.

HSBC also cut BioNTech’s price target to $111.00 from $124.00. Shares of the company, whose fortunes are tied to vaccine-related profit-sharing payments from Pfizer, were recently plunging 6% to $97.39.

Cummins cut to Underweight at JPMorgan

Cummins (NYSE:) was downgraded by JPMorgan to Underweight from Neutral and cut its price target to $255.00 from $270.00, as reported in real time on

The company is set to report its Q3/23 earnings on Nov 2. Street estimates stand at $4.76 for EPS and $8.21 billion for revenues.

Shares dipped on the downgrade in the premarket, but were up fractionally in recent regular-session trading at $228.49. receives another downgrade (NASDAQ:) was cut by Bernstein to Market Perform from Outperform, with the price target slashed to $31.00 from $55.00.

The analysts highlighted the stock’s decline this year, which intensified after the company’s weaker-than-expected trajectory for the remainder of 2023. With the company’s struggles now evident to most, and despite it citing conservatism for its growth outlook, Bernstein remained skeptical of JD’s turnaround potential, especially given its vague strategies and limited growth expectations.

This follows a pair of downgrades last week: Morgan Stanley cut the company to Equalweight from Overweight, setting a price target at $33.00, down from $55.00, and Macquarie moved to Neutral from Outperform, with a revised price target of $32.00 (from $52.00).

Still, shares were lately up 1.9% to $27.56.

Previous Post
U.S. stocks rise ahead of a wave of corporate earnings reports, economic data
Next Post
Pfizer bags Jefferies buy call after guidance cut: 5 big analyst picks

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.
You need to agree with the terms to proceed

Invest on crypto with Gianluca Vacchi project and start making money now
Win money trading on Amazon